Member Contact: Leanne Daly
Position: Business Development Director
Industry: Biotech & Pharmaceuticals
Imagion Biosystems, Ltd is an Australian medical device developer with a U.S. based research and development operation, listed on the Australian Securities Exchange (ASX: IBX). Imagion has developed a new medical imaging technology which can detect specific cancers non-invasively. The proprietary technology uses magnetic nanoparticles with tumour-targeting antibodies to “tag” specific cancers. Only those particles that are attached to the tumour are measured by the sensors, while unattached nanoparticles are not detected greatly improving sensitivity. Unlike other types of scans, this detection technology does not expose the patient to ionising radiation or radioactive tracers, and uses magnetic fields orders of magnitude less than that used in MRI. Researchers from the world leading MD Anderson Cancer Centre have been working with the company for 3 years. Preclinical evidence supports the technology is more sensitive than current imaging technologies, thus facilitating earlier detection, and will differentiate malignant from benign tumours.
Working with MD Anderson, Monash Uni and the Peter Mac Cancer Institute the company plans to undertake clinical translational development of three programs in its R&D pipeline: the staging of HER2+ breast cancer to minimize use of invasive lymphadenectomy; the primary diagnosis of prostate cancer to reduce the need for prostate biopsy; and the detection of epithelial ovarian carcinoma in women as an alternative to late stage detection by trans-vaginal ultrasound.